WO2004112786A3 - Gaboxadol for treating depression and other affective disorders - Google Patents
Gaboxadol for treating depression and other affective disorders Download PDFInfo
- Publication number
- WO2004112786A3 WO2004112786A3 PCT/DK2004/000459 DK2004000459W WO2004112786A3 WO 2004112786 A3 WO2004112786 A3 WO 2004112786A3 DK 2004000459 W DK2004000459 W DK 2004000459W WO 2004112786 A3 WO2004112786 A3 WO 2004112786A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gaboxadol
- treating depression
- affective disorders
- pharmaceutical composition
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Priority Applications (23)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0410857-4A BRPI0410857A (en) | 2003-06-25 | 2004-06-25 | method for treating depression, use of gaboxadol, and pharmaceutical composition |
EA200600101A EA200600101A1 (en) | 2003-06-25 | 2004-06-25 | TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS |
SI200431414T SI1641456T1 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
PL04738956T PL1641456T3 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
AT04738956T ATE459353T1 (en) | 2003-06-25 | 2004-06-25 | GABOXADOL USED TO TREAT DEPRESSION AND OTHER AFFECTIVE DISORDERS |
NZ543586A NZ543586A (en) | 2003-06-25 | 2004-06-25 | Gaboxadol4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol or THIP in monotherapy for treating depression and other affective disorders |
AU2004248890A AU2004248890A1 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
DK04738956.4T DK1641456T3 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for the treatment of depression and other affective disorders |
DE602004025808T DE602004025808D1 (en) | 2003-06-25 | 2004-06-25 | GABOXADOL FOR THE TREATMENT OF DEPRESSIONS AND OTHER AFFECTIVE DISORDERS |
MEP-19/08A MEP1908A (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
YUP-2005/0911A RS20050911A (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
JP2006515735A JP2007508236A (en) | 2003-06-25 | 2004-06-25 | How to treat depression and other affective disorders |
MXPA05013016A MXPA05013016A (en) | 2003-06-25 | 2004-06-25 | Aboxadol for treating depression and other affective disorders. |
MEP-2008-19A ME00030B (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
EP04738956A EP1641456B1 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
CA002529805A CA2529805A1 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
US11/020,632 US20050234093A1 (en) | 2003-06-25 | 2004-12-22 | Treatment of depression and other affective disorders |
IS8138A IS8138A (en) | 2003-06-25 | 2005-11-21 | Gaboxadol for the treatment of depression and other psychiatric disorders |
IL172631A IL172631A0 (en) | 2003-06-25 | 2005-12-15 | Gaboxadol for treating depression and other affective disorders |
NO20060229A NO20060229L (en) | 2003-06-25 | 2006-01-16 | Gaboxadol for the treatment of depression and other affective disorders |
US12/389,764 US20090203731A1 (en) | 2003-06-25 | 2009-02-20 | Treatment of depression and other affective disorders |
IL202106A IL202106A0 (en) | 2003-06-25 | 2009-11-12 | Gaboxadol for treating depression and other affective disorders |
HR20100276T HRP20100276T1 (en) | 2003-06-25 | 2010-05-18 | Gaboxadol for treating depression and other affective disorders |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48301903P | 2003-06-25 | 2003-06-25 | |
US60/483,019 | 2003-06-25 | ||
DKPA200300956 | 2003-06-25 | ||
DKPA200300956 | 2003-06-25 | ||
US53512304P | 2004-01-07 | 2004-01-07 | |
US60/535,123 | 2004-01-07 | ||
DKPA200400016 | 2004-01-07 | ||
DKPA200400016 | 2004-01-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/020,632 Continuation-In-Part US20050234093A1 (en) | 2003-06-25 | 2004-12-22 | Treatment of depression and other affective disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004112786A2 WO2004112786A2 (en) | 2004-12-29 |
WO2004112786A3 true WO2004112786A3 (en) | 2005-04-14 |
Family
ID=33545397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000459 WO2004112786A2 (en) | 2003-06-25 | 2004-06-25 | Gaboxadol for treating depression and other affective disorders |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP1641456B1 (en) |
JP (1) | JP2007508236A (en) |
AT (1) | ATE459353T1 (en) |
AU (1) | AU2004248890A1 (en) |
BR (1) | BRPI0410857A (en) |
CY (1) | CY1110046T1 (en) |
DE (1) | DE602004025808D1 (en) |
DK (1) | DK1641456T3 (en) |
ES (1) | ES2341004T3 (en) |
HR (1) | HRP20100276T1 (en) |
IL (2) | IL172631A0 (en) |
MX (1) | MXPA05013016A (en) |
NZ (1) | NZ543586A (en) |
PL (1) | PL1641456T3 (en) |
PT (1) | PT1641456E (en) |
SI (1) | SI1641456T1 (en) |
WO (1) | WO2004112786A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032553A1 (en) * | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
WO2005060968A1 (en) | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
ATE454140T1 (en) | 2004-02-18 | 2010-01-15 | Sepracor Inc | DOPAMINE AGONIST COMBINATION THERAPY WITH SEDATIVES TO IMPROVE SLEEP QUALITY |
GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
EP1848420A4 (en) | 2005-01-28 | 2008-01-23 | Merck & Co Inc | Polymorphic forms of a gabaa agonist |
US20080262029A1 (en) * | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
US20090143335A1 (en) * | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
JP2012501301A (en) * | 2008-09-01 | 2012-01-19 | ハー・ルンドベック・アクチエゼルスカベット | Pharmaceutical composition comprising gaboxadol and PAT1 inhibitor or OAT inhibitor |
PT3274331T (en) | 2015-03-24 | 2020-04-02 | H Lundbeck As | Manufacture of 4,5,6,7-tetrahydroisozaxolo[5,4-c]pyridin-3-ol |
MX2019005779A (en) * | 2016-11-22 | 2019-08-22 | Ovid Therapeutics Inc | Methods of treating developmental disorders and/or seizure disorders with flupirtine. |
US20180338959A1 (en) * | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
CN112601524A (en) * | 2018-04-06 | 2021-04-02 | 奥维德医疗公司 | Use of gaboxadol for treating substance use disorders |
KR20210062662A (en) | 2018-09-20 | 2021-05-31 | 오비드 테라퓨틱스 인크. | Use of Gaboksadol for the treatment of Tourette's syndrome, ticks and stuttering |
GB2594616A (en) | 2018-11-21 | 2021-11-03 | Certego Therapeutics Inc | Gaboxadol for reducing risk of suicide and rapid relief of depression |
MX2021005994A (en) * | 2018-11-21 | 2021-09-14 | Certego Therapeutics Inc | Combination of gaboxadol and lithium for the treatment of psychiatric disorders. |
AU2019405489A1 (en) | 2018-12-17 | 2021-06-10 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
KR20220114572A (en) | 2019-12-18 | 2022-08-17 | 오비드 테라퓨틱스 인크. | Gaboxadol for Therapeutic Treatment of 1p36 Deletion Syndrome |
TW202208373A (en) | 2020-05-20 | 2022-03-01 | 美商瑟泰戈治療學股份有限公司 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1254668A2 (en) * | 2001-05-01 | 2002-11-06 | Pfizer Products Inc. | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270278A (en) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | CYCLIC AMINO ACIDS |
DE19525598C2 (en) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | sleeping pills |
AR031473A1 (en) * | 2000-11-20 | 2003-09-24 | Lundbeck & Co As H | GABA INTENSIFIERS IN THE TREATMENT OF DISEASES RELATED TO A REDUCED NEUROSTEROID ACTIVITY |
WO2002094225A1 (en) | 2001-05-21 | 2002-11-28 | H. Lundbeck A/S | Granular preparations of gaboxadol |
-
2004
- 2004-06-25 PT PT04738956T patent/PT1641456E/en unknown
- 2004-06-25 MX MXPA05013016A patent/MXPA05013016A/en active IP Right Grant
- 2004-06-25 BR BRPI0410857-4A patent/BRPI0410857A/en not_active IP Right Cessation
- 2004-06-25 EP EP04738956A patent/EP1641456B1/en not_active Expired - Lifetime
- 2004-06-25 DE DE602004025808T patent/DE602004025808D1/en not_active Expired - Lifetime
- 2004-06-25 EP EP09173892A patent/EP2145620A3/en not_active Withdrawn
- 2004-06-25 JP JP2006515735A patent/JP2007508236A/en active Pending
- 2004-06-25 AT AT04738956T patent/ATE459353T1/en not_active IP Right Cessation
- 2004-06-25 DK DK04738956.4T patent/DK1641456T3/en active
- 2004-06-25 SI SI200431414T patent/SI1641456T1/en unknown
- 2004-06-25 ES ES04738956T patent/ES2341004T3/en not_active Expired - Lifetime
- 2004-06-25 WO PCT/DK2004/000459 patent/WO2004112786A2/en active Application Filing
- 2004-06-25 NZ NZ543586A patent/NZ543586A/en unknown
- 2004-06-25 AU AU2004248890A patent/AU2004248890A1/en not_active Abandoned
- 2004-06-25 PL PL04738956T patent/PL1641456T3/en unknown
-
2005
- 2005-12-15 IL IL172631A patent/IL172631A0/en unknown
-
2009
- 2009-11-12 IL IL202106A patent/IL202106A0/en unknown
-
2010
- 2010-05-14 CY CY20101100433T patent/CY1110046T1/en unknown
- 2010-05-18 HR HR20100276T patent/HRP20100276T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1254668A2 (en) * | 2001-05-01 | 2002-11-06 | Pfizer Products Inc. | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression |
Non-Patent Citations (1)
Title |
---|
CHRISTENSEN A V ET AL: "Pharmacodynamic effects and possible therapeutic uses of THIP, a specific GABA-agonist.", PHARMACEUTISCH WEEKBLAD. SCIENTIFIC EDITION. 22 OCT 1982, vol. 4, no. 5, 22 October 1982 (1982-10-22), pages 145 - 153, XP008035614, ISSN: 0167-6555 * |
Also Published As
Publication number | Publication date |
---|---|
PL1641456T3 (en) | 2010-08-31 |
CY1110046T1 (en) | 2015-01-14 |
IL202106A0 (en) | 2010-06-16 |
EP1641456B1 (en) | 2010-03-03 |
EP1641456A2 (en) | 2006-04-05 |
BRPI0410857A (en) | 2006-07-04 |
SI1641456T1 (en) | 2010-06-30 |
PT1641456E (en) | 2010-06-01 |
HRP20100276T1 (en) | 2010-06-30 |
ES2341004T3 (en) | 2010-06-14 |
DK1641456T3 (en) | 2010-06-21 |
IL172631A0 (en) | 2006-04-10 |
ATE459353T1 (en) | 2010-03-15 |
DE602004025808D1 (en) | 2010-04-15 |
WO2004112786A2 (en) | 2004-12-29 |
EP2145620A2 (en) | 2010-01-20 |
JP2007508236A (en) | 2007-04-05 |
MXPA05013016A (en) | 2006-03-02 |
AU2004248890A1 (en) | 2004-12-29 |
NZ543586A (en) | 2009-07-31 |
EP2145620A3 (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL172631A0 (en) | Gaboxadol for treating depression and other affective disorders | |
WO2007064797A3 (en) | Inhibitors of c-met and uses thereof | |
WO2006124748A3 (en) | Multicyclic compounds and methods of their use | |
WO2006073457A8 (en) | Bioactive compounds and methods of uses thereof | |
WO2010003120A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2006096434A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders | |
WO2009108720A3 (en) | Antagonists of prostaglandin d2 receptors | |
EP2559694A3 (en) | Azaindoles useful as inhibitors of Janus kinases | |
WO2006002097A3 (en) | Retinal derivatives and methods for the use thereof for the treatment of visual disorders | |
WO2005063232A8 (en) | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2007115305A3 (en) | Oral dosage forms including an antiplatelet agent and an acid inhibitor | |
MX2007010560A (en) | Roflumilast for the treatment of diabetes mellitus. | |
WO2007106436A3 (en) | Photoactive compounds and compositions and uses thereof | |
WO2007067519A3 (en) | The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions | |
WO2007084857A3 (en) | Methods and compositions for treating cell proliferative disorders | |
WO2009002423A3 (en) | Polycyclic guanine derivatives and use thereof | |
WO2006056696A3 (en) | 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof | |
WO2006056695A8 (en) | Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof | |
CL2008003231A1 (en) | Substituted 1,3-dihydro-5-isobenzofurancarbonitrile derivative compounds, selective serotonin reuptake inhibitors; pharmaceutical composition; preparation procedure; Useful in the treatment and / or prevention of premature ejaculation. | |
WO2006087629A3 (en) | Rapidly disintegrating composition of olanzapine | |
WO2006128120A3 (en) | Novel lapachone compounds and methods of use thereof | |
WO2008094054A3 (en) | 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders | |
UA90656C2 (en) | Gaboxadol for treating depression | |
MEP1908A (en) | Gaboxadol for treating depression and other affective disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0911 Country of ref document: YU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11020632 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 543586 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/09356 Country of ref document: ZA Ref document number: 200509356 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12005502115 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/013016 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004738956 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004248890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 172631 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2529805 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006515735 Country of ref document: JP Ref document number: 05129157 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057024823 Country of ref document: KR Ref document number: 20048175886 Country of ref document: CN Ref document number: 3506/CHENP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2004248890 Country of ref document: AU Date of ref document: 20040625 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004248890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200600117 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200600101 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057024823 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004738956 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0410857 Country of ref document: BR |